Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV003622250 | SCV004548689 | pathogenic | Hyper-IgM syndrome type 1 | 2022-11-23 | criteria provided, single submitter | clinical testing | This variant disrupts a region of the CD40LG protein in which other variant(s) (p.Gln232*) have been determined to be pathogenic (PMID: 8550833, 18805740). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with CD40LG-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gly199Argfs*2) in the CD40LG gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 63 amino acid(s) of the CD40LG protein. |